Paper39259258
Enhancing therapy with nano-based delivery systems: exploring the bioactive properties and effects of apigenin.
Kumar G and 8 others. Ther Deliv, 2024. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Enhancing therapy with nano-based delivery systems: exploring the bioactive properties and effects of apigenin. Papers, record 39259258. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39259258
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Enhancing therapy with nano-based delivery systems: exploring the bioactive properties and effects of apigenin.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Apigenin | Major topic |
| Humans | |
| Animals | |
| Biological Availability | |
| Solubility | |
| Drug Delivery Systems | |
| Nanoparticles | |
| Nanotechnology | |
| Nanoparticle Drug Delivery System |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| RGP2/317/45 | Deanship of Research and Graduate Studies at King Khalid University | PubMed | ||
| LA/P/0101/2020 | Fundação para a Ciência e a Tecnologia | PubMed |
Source PubMed
References93
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35495935 | Protective Roles of Apigenin Against Cardiometabolic Diseases: A Systematic Review. | Front Nutr | 2022 | https://conductscience.org/library/papers/35495935 | PubMed |
| 2 | 34084146 | Does Oral Apigenin Have Real Potential for a Therapeutic Effect in the Context of Human Gastrointestinal and Other Cancers? | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34084146 | PubMed |
| 3 | 24269286 | Enhanced in vitro and in vivo skin deposition of apigenin delivered using ethosomes. | Int J Pharm | 2014 | https://conductscience.org/library/papers/24269286 | PubMed |
| 4 | 24971492 | Apigenin inhibits enterovirus 71 replication through suppressing viral IRES activity and modulating cellular JNK pathway. | Antiviral Res | 2014 | https://conductscience.org/library/papers/24971492 | PubMed |
| 5 | 24266259 | Micelles of TPGS modified apigenin phospholipid complex for oral administration: preparation, in vitro and in vivo evaluation. | J Biomed Nanotechnol | 2013 | https://conductscience.org/library/papers/24266259 | PubMed |
| 6 | 25565442 | How to overcome the limitations of current insulin administration with new non-invasive delivery systems. | Ther Deliv | 2015 | https://conductscience.org/library/papers/25565442 | PubMed |
| 7 | 34740050 | Apigenin-oxymatrine binary co-amorphous mixture: Enhanced solubility, bioavailability, and anti-inflammatory effect. | Food Chem | 2022 | https://conductscience.org/library/papers/34740050 | PubMed |
| 8 | 35816909 | Polymer-based drug delivery systems for anticancer drugs: A systematic review. | Cancer Treat Res Commun | 2022 | https://conductscience.org/library/papers/35816909 | PubMed |
| 9 | 31416279 | The Stability and Activity Changes of Apigenin and Luteolin in Human Cervical Cancer Hela Cells in Response to Heat Treatment and Fe2+/Cu2+ Addition. | Foods | 2019 | https://conductscience.org/library/papers/31416279 | PubMed |
| 10 | 36007853 | Apigenin in cancer therapy: From mechanism of action to nano-therapeutic agent. | Food Chem Toxicol | 2022 | https://conductscience.org/library/papers/36007853 | PubMed |
| 11 | 35096502 | A Comprehensive Review on Novel Liposomal Methodologies, Commercial Formulations, Clinical Trials and Patents. | Bionanoscience | 2022 | https://conductscience.org/library/papers/35096502 | PubMed |
| 12 | 36915508 | Apigenin-coated gold nanoparticles as a cardioprotective strategy against doxorubicin-induced cardiotoxicity in male rats via reducing apoptosis. | Heliyon | 2023 | https://conductscience.org/library/papers/36915508 | PubMed |
| 13 | 30986716 | Apoptosis induced by luteolin in breast cancer: Mechanistic and therapeutic perspectives. | Phytomedicine | 2019 | https://conductscience.org/library/papers/30986716 | PubMed |
| 14 | 37447573 | Amelioration of Cancer Employing Chitosan, Its Derivatives, and Chitosan-Based Nanoparticles: Recent Updates. | Polymers (Basel) | 2023 | https://conductscience.org/library/papers/37447573 | PubMed |
| 15 | 31759101 | Dendrimers in the context of nanomedicine. | Int J Pharm | 2020 | https://conductscience.org/library/papers/31759101 | PubMed |
| 16 | 34866166 | Nanoparticles for Cancer Therapy: Current Progress and Challenges. | Nanoscale Res Lett | 2021 | https://conductscience.org/library/papers/34866166 | PubMed |
| 17 | 33583219 | Liposomes and transferosomes: a breakthrough in topical and transdermal delivery. | Ther Deliv | 2021 | https://conductscience.org/library/papers/33583219 | PubMed |
| 18 | 34996205 | Aptamer-Conjugated Apigenin Nanoparticles To Target Colorectal Carcinoma: A Promising Safe Alternative of Colorectal Cancer Chemotherapy. | ACS Appl Bio Mater | 2018 | https://conductscience.org/library/papers/34996205 | PubMed |
| 19 | 38026534 | Dually Active Apigenin-Loaded Nanostructured Lipid Carriers for Cancer Treatment. | Int J Nanomedicine | 2023 | https://conductscience.org/library/papers/38026534 | PubMed |
| 20 | 36145264 | Bilosomes as Nanoplatform for Oral Delivery and Modulated In Vivo Antimicrobial Activity of Lycopene. | Pharmaceuticals (Basel) | 2022 | https://conductscience.org/library/papers/36145264 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42910236 | Advancements in Nanomedicine Platforms and Solid-State Engineering for Enhancing the Solubility of Apigenin: A Narrative Review. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42910236 | PubMed |
| 42683198 | Natural Medicines Modulating Tumor Perineural Invasion: Regulatory Mechanisms and Therapeutic Potential. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42683198 | PubMed |
| 42365116 | Unveiling the potential of solid lipid nanoparticles of apigenin-Cu(II) coordinated nanocomplex in colon cancer. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/42365116 | PubMed |
| 41323822 | Overcoming the Low Bioavailability of Apigenin: The Therapeutic Efficacy for Androgenetic Alopecia Through Topical Administration. | Food Sci Nutr | 2025 | https://conductscience.org/library/papers/41323822 | PubMed |
| 40806510 | Isorhamnetin: Reviewing Recent Developments in Anticancer Mechanisms and Nanoformulation-Driven Delivery. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40806510 | PubMed |
| 40788176 | Unlocking the full potential of piperine-loaded nanocarriers for cancer treatment. | Ther Deliv | 2025 | https://conductscience.org/library/papers/40788176 | PubMed |
| 39686635 | An Updated Review Deciphering Apigenin Nanostructures as Promising Therapeutic Efficiency in Human Carcinomas. | Curr Med Chem | 2025 | https://conductscience.org/library/papers/39686635 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39259258
GET https://conductscience.org/api/papers/v1/39259258/references?page=2